Up next are two clinical trials, a phase-two clinical trial for GP1681 in the area of Covid-19 and a separate clinical that will determine how it works with CAR-T patients. It’s shaping up to be a busy year for Pittsburgh-based CytoAgents, an early stage pharmaceutical company based in Pittsburgh whose drug candidate. Read more >>
Sue Nolin VP, Inside Sales, Wasabi Technologies — When it comes to growing sales and its channel team, Wasabi…
read moreWhen you think of medical innovation, you may think of San Diego, Boston or the San Francisco Bay area….
read moreOn this Thanksgiving Eve, a holiday miracle for a South Florida woman who is legally blind.
On Thanksgiving Day, for…
Boston’s startups and tech companies were busy in September, pulling in collective billions from VCs and other investors. Here’s…
read moreKnipBio has successfully completed a series of trials examining the efficiency of its single-cell protein ingredient KnipBio Meal (KBM)…
read moreRegroup was honored to be the only mass notification platform winner due to exceptional innovation, ease-of-use, and providing the…
read moreThis past month has been nothing short of miraculous in the personal and professional life of K.C. Ryder, a…
read moreA recent study by researchers at the University of New Brunswick (UNB) indicates that tricompartment unloader knee braces are…
read moreA wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will…
read moreeSight, the makers of the eSight electronic glasses, is permanently dropping the pricing of its eSight glasses from $10,000…
read more